Kidney Sodium Functional Imaging: Evaluation of Kidney Medullary Sodium Content Using 23Na MRI in Kidney Disease

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The corticomedullary gradient is largely responsible for developing the gradients that are needed to concentrate urine (more solutes and less water). The ability of the kidneys to produce concentrated urine is a major determinant of the ability to survive the warm weather. When temperatures are high, we lose water through sweat, and so the kidneys retain water to maintain fluidity in the blood. The maintenance of a sodium (salt) gradient is required for urine concentration because increased medullary sodium concentration increases the reabsorption of water into the kidney, to be redistributed in the blood. The purpose of this study is to know if the corticomedullary gradient is altered in patients across a wide spectrum of kidney disease using sodium Magnetic Resonance Imaging (MRI), a machine that takes pictures and measures the salt content in the kidneys. 23Na kidney MRI, will provide functional MR of the kidney as a non-invasive tool to describe medullary function to improve management of chronic and kidney disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age ≥ 18 years

• For healthy controls: lack of kidney disease, heart failure, liver cirrhosis and peripheral edema

• For CKD stage 1-5: Estimated GFR \< 90 mL/min/1.73m²

• For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy

Locations
Other Locations
Canada
Victoria Hospital, London Health Sciences Centre
RECRUITING
London
Contact Information
Primary
Christopher W McIntyre, MD
christopher.mcintyre@lhsc.on.ca
5196858500
Backup
Sandrine Lemoine, MD
Time Frame
Start Date: 2021-09-16
Estimated Completion Date: 2026-02-28
Participants
Target number of participants: 200
Treatments
Adult CKD stage 1-5 participants
* Age greater than or equal to 18 years~* Estimated GFR \< 90 mL/min/1.73m²
Adult transplanted participants
• Age greater than or equal to 18 years
Adult dialysis participants
* Age greater than or equal to 18 years~* More than 3 months duration of therapy
Adult ADPKD
• Age greater than or equal to 18 years
Adults treated for nephrolithiasis
• Age greater than or equal to 18 years
Adult healthy controls including kidney donors
* Age greater than or equal to 18 years~* Lack of kidney disease, heart failure, liver cirrhosis and peripheral
Sponsors
Leads: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

This content was sourced from clinicaltrials.gov